- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977649
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients (RESET BRAIN)
A RandomizEd, Double-blind, Cross-over Study to Assess Erenumab effecT on BRAIN Networks Function and Structure in Comparison to Placebo in Episodic Migraine Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double blind, placebo-controlled trial with a 2-sequence, 2-period, 2-treatment crossover design. The study population will consist of adult male and female subjects with a documented history of episodic migraine (4 to 14 baseline migraine days), who have failed at least 2 previous migraine prophylactic treatment for lack of efficacy or tolerability. After a run-in phase of 4 weeks, patients will be randomized, according to a 1:1 ratio, to a 24 weeks of treatment, as follow:
- Sequence 1: A/B
- Sequence 2: B/A where: A=monthly subcutaneous erenumab 140 mg for 12 weeks; B=monthly subcutaneous masked placebo for 12 weeks
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
L Aquila, Italy
- Novartis Investigative Site
-
Napoli, Italy, 80138
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20133
- Novartis Investigative Site
-
Milano, MI, Italy, 20132
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Italy, 27100
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study History of migraine with or without aura for at least 12 months prior to screening 4. Migraine frequency: ≥ 4 and < 15 migraine days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary calculation
- Headache frequency: <15 headache days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary calculation
- Failure to 2 or more previous treatment categories locally indicated for migraine prophylaxis due to either lack of efficacy or poor tolerability
Exclusion Criteria:
- History of cluster headache or hemiplegic migraine headache
- History of chronic pain disorders and neuropathic pain
- History of head trauma or seizure or major psychiatric disorders or suicidal ideation/behavior at any time before screening
- Currently, receiving any other prophylactic treatment for migraine and/or prohibited medications, non-pharmacologic interventions or devices (any substance, non-pharmacologic intervention or device acting at central nervous system), or less than 60 days or 5 half-lives prior to the start of the baseline period, during the baseline period, or treatment period
- Exposure to botulinum toxin in the head and/or neck region within 4 months prior to the start of the baseline period, during the baseline period, or treatment period.
Taken the following for any indication in any month during the 2 months prior to the start of the baseline period:
- Ergotamines or triptans on ≥ 10 days per month, or
- Simple analgesics (non-steroidal anti-inflammatory drugs [NSAIDs], acetaminophen) on ≥ 15 days per month, or
- Opioid- or butalbital-containing analgesics on ≥4 days per month.
- Previous exposure to erenumab or exposure to any other prophylactic CGRP-targeted therapy (prior to and during the study)
- History or evidence of any other unstable or clinically significant medical condition that in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
- Subject has any clinically significant vital sign, laboratory, or electrocardiogram (ECG) abnormality during screening that, in the opinion of the investigator, could pose a risk to subject safety or interfere with the study evaluation
- Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records or patient self-report
- Pregnant or breastfeeding
- All the clinical conditions for which undergoing an MRI scan is contraindicated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: erenumab
monthly subcutaneous erenumab 140 mg for 12 weeks
|
erenumab 140 mg sc every 4 weeks
|
Placebo Comparator: placebo
monthly subcutaneous masked placebo for 12 weeks.
|
placebo sc every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
z-score maps change difference between-treatment-groups
Time Frame: baseline, month 3, month 6
|
z score maps are measures of resting state functional connectivity strength in the brain areas involved in pain processing
|
baseline, month 3, month 6
|
z-score maps difference between clinical response groups within the two treatment groups.
Time Frame: baseline, month 3, month 6
|
clinical response assessed as reduction by 50% in monthly migraine days ,MMD, in the last month vs baseline. z score maps relative to resting state functional connectivity strength in the brain areas involved in pain processing |
baseline, month 3, month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation (by treatment groups and in all patients) between the changes in the resting state functional connectivity strength, measured as z-score maps, and clinical outcomes
Time Frame: month 3, month 6
|
clinical outcomes: the percentage of change in monthly migraine, b. the reduction in monthly average severity of migraine pain, c. the percentage of reduction in monthly number of days with use of acute treatments, d. the change in HIT-6 score
|
month 3, month 6
|
Between-treatment-groups difference in change of resting state functional connectivity strength, from baseline to month 3 of treatment, measured as z-score maps. in the brain regions involved in migraine symptoms
Time Frame: baseline, month 3, month 6
|
migraine symptoms: a. sensory hypersensitivity (allodynia) b. visual or auditory hypersensitivity (photophobia or phonophobia) c. neurovegetative symptoms (nausea) d. altered emotional control of pain
|
baseline, month 3, month 6
|
Correlation (by treatment group and in all patients) between of the changes in the resting state functional connectivity strength of the areas involved in migraine symptoms and the reduction of the respective symptoms
Time Frame: month 3, month 6
|
the clinical response here is described as reduction of the migraine symptoms: changes in the Allodynia Symptom Checklist 12 (ASC-12) score as measure of allodynia, the percentage changes in number of days with photophobia and phonophobia, and the percentage changes in number of days with nausea, changes in HADS score as measure of anxiety and depressive behaviour
|
month 3, month 6
|
Baseline resting state functional connectivity strength will be evaluated by treatment group and in all patients as potential predictors of treatment clinical response defined by the achievement of at least 50% reduction of monthly migraine days
Time Frame: baseline, month 3, month 6
|
baseline functional MRI markers predictive of good clinical response to erenumab
|
baseline, month 3, month 6
|
Changes in z-score maps from baseline to month 3 of erenumab treatment and from baseline to month 6 with 3 months with erenumab followed by 3 months of placebo
Time Frame: baseline, month 3, month 6
|
the effects of the erenumab discontinuation on fMRI after 3 months of placebo treatment
|
baseline, month 3, month 6
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Erenumab
Other Study ID Numbers
- CAMG334AIT03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Disorders
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
Vastra Gotaland RegionNot yet recruiting
Clinical Trials on erenumab
-
AmgenNovartisRecruitingMigraineUnited States, Japan, Belgium, Canada, United Kingdom, Germany, Poland, Hungary, Italy, Colombia, Russian Federation, Finland, Puerto Rico
-
AmgenNovartisRecruitingMigraineUnited States, Spain, Japan, Poland, Belgium, Canada, United Kingdom, Germany, Hungary, Italy, Colombia, Russian Federation, Portugal, Switzerland, Finland, Puerto Rico
-
AmgenCompletedMigraineUnited States, Germany, Denmark, Canada, Finland, Sweden, Norway
-
AmgenCompletedMigraine HeadacheUnited States, Austria, Australia, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
-
University of Maryland, BaltimoreAmgenTerminatedTrigeminal NeuropathyUnited States
-
Massachusetts General HospitalUnited States Department of Defense; Recordati Rare DiseasesRecruitingPain, Chronic | Schwannomatosis | SchwannomasUnited States
-
David Jang, M.D.AmgenCompleted
-
Merle DiamondClinvest Research, LLC; Smith, Timothy R., M.D.Completed